Table 3.

NSABP FB-7: pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

Treatment arms, n = 42 each arm	Total pCR	P-value for pCR T vs Other Arms in all patientsa	pCR HR+	P-value for pCR T vs Other Arms T in HR+b	pCR HR−	P-value for pCR T vs Other Arms T in HR−b	P HR+ vs HR−
Arm 1 (T)	16/41 (39.0%)	NA	8/27 (29.6%)	NA	8/14 (57.1%)	NA	0.11
Arm 2 (N)	14/42 (33.3%)	0.63	8/29 (27.6%)	1	6/13 (46.2%)	0.71	0.30
Arm 3 (T plus N)	21/42 (50%)	0.22	7/23 (30.4%)	1	14/19 (73.7%)	0.46	0.01
All arms	51/126 (40%)		23/79 (29%)		28/46 (61%)		0.001

T trastuzumab, N neratinib

^aCMH test stratified for the time period the patients were randomized to the study (prior/after the addition of arm 3)

^bFisher’s exact test